Climb Bio (CLYM) Accounts Payables (2020 - 2026)
Climb Bio's (CLYM) quarterly Accounts Payables came in at $860000.0 in Q1 2026, up 10.68% YoY from $777000.0 in Q1 2025, and down 62.1% on a QoQ basis from $2.3 million in Q4 2025.
Climb Bio (CLYM) Accounts Payables (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Accounts Payables data on file, last reported at $860000.0 in Q1 2026.
- Quarterly Accounts Payables rose 10.68% year-over-year to $860000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $860000.0 (up 10.68% YoY) and the FY2025 annual result came in at $2.3 million, up 221.84% from the prior year.
- Accounts Payables fell to $860000.0 in Q1 2026, from $2.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.3 million in Q4 2025 to a low of $66000.0 in Q4 2023.
- A 5-year average of $800882.4 and a median of $777000.0 in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 4568.75% — and 2023, when it sank 91.2%.
- Tracing CLYM's Accounts Payables over 5 years: stood at $750000.0 in 2022, then slumped by 91.2% to $66000.0 in 2023, then surged by 968.18% to $705000.0 in 2024, then jumped by 221.84% to $2.3 million in 2025, then sank by 62.1% to $860000.0 in 2026.
- The last three Accounts Payables figures came in at $860000.0 (Q1 2026), $2.3 million (Q4 2025), and $477000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 860,000.00 |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 477,000.00 |
| Jun 30, 2025 | 946,000.00 |
| Mar 31, 2025 | 777,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Sep 30, 2024 | 291,000.00 |
| Jun 30, 2024 | 509,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Dec 31, 2023 | 66,000.00 |
| Sep 30, 2023 | 736,000.00 |
| Jun 30, 2023 | 878,000.00 |
| Mar 31, 2023 | 864,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.06 Mn |
| Mar 31, 2022 | 847,000.00 |
| Dec 31, 2021 | 1.40 Mn |
| Sep 30, 2021 | 32,000.00 |